Petros Pharmaceuticals, Inc. (PTPI)
$1.47
-0.13 (-8.13%)
Rating:
Recommendation:
-
| Symbol | PTPI |
|---|---|
| Price | $1.47 |
| Beta | 2.232 |
| Volume Avg. | 0.05M |
| Market Cap | 3.236M |
| Shares () | - |
| 52 Week Range | 0.917-9.54 |
| 1y Target Est | - |
| DCF Unlevered | PTPI DCF -> | |
|---|---|---|
| DCF Levered | PTPI LDCF -> | |
| ROE | -1773.85% | Strong Sell |
| ROA | -592.89% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 125.33% | Buy |
| P/E | -0.24 | Neutral |
| P/B | 0.45 | Neutral |
Latest PTPI news
About
Download (Excel)Mr. John David Shulman
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.